ACADIA PHARMACEUTICALS INC 4

EVP Elizabeth H.Z. Thompson had 32,272 RSUs vest into ACADIA common stock and then sold 16,558 shares around $26.13–$26.17 solely to cover taxes, ending with 18,994 shares owned.

On July 29, 2026, Elizabeth H.Z. Thompson, EVP, Head of Research & Development at ACADIA Pharmaceuticals Inc., acquired 32,272 shares of common stock upon the vesting/settlement of an equivalent number of restricted stock units, increasing her direct holdings to 35,552 shares. In connection with this vesting, on July 30, 2026 she executed mandatory sales to cover withholding taxes and related obligations, selling 16,508 shares at $26.13 per share and 50 shares at $26.17 per share, for total proceeds of roughly $432,627, leaving her with 18,994 directly owned shares after the tax-related dispositions. The RSUs represent standard equity compensation, with 50% vesting on July 29, 2026 and the remaining 50% vesting in two annual installments on July 29, 2027 and July 29, 2028, and the tax-cover sales were effected under a Rule 10b5-1-compliant arrangement.

Filing Facts

CIK

1070494

Ticker

ACAD

Form

4

Source Type

fda

Accession

0001861477-26-000005

Alert Tier

5